



# Supporting Information

Belgacem and Borodinsky 10.1073/pnas.1419690112




**Fig. S1.** Patched 1 expression is inhibited by PKA stimulation and electrical activity. Relative Patched 1 transcript levels from neural plates or spinal cords were quantified using qRT-PCR after 8 h incubation with 20  $\mu$ M forskolin, voltage-gated  $\text{Na}^+$  and  $\text{Ca}^{2+}$  channel blockers (VGcblock), or vehicle only (control). Primers specific for Patched 1 were used, and ODC gene transcript was used as normalizer. Graph shows mean  $\pm$  SEM fold change of normalized transcript levels compared with control at each developmental stage;  $n = 6$ ; \* $P < 0.05$  and \*\*\* $P < 0.00001$ .




**Fig. S2.** Stimulation of voltage-gated Na<sup>+</sup> channels does not affect Ca<sup>2+</sup> transients or Gli activity in the neural plate. (A) Two-cell-stage embryos were injected with the genetically encoded Ca<sup>2+</sup> sensor, GCaMP6s, and time-lapse imaged at neural plate stages (stage 14, 16.25 hpf) for 30 min at 0.2 Hz in the absence or presence of 1  $\mu$ M veratridine, voltage-gated Na<sup>+</sup> channel agonist. Graph shows mean  $\pm$  SEM percentage of neural plate cells exhibiting Ca<sup>2+</sup> transients in the presence or absence of veratridine;  $n = 5$ . (B) Neural plates from embryos expressing 8GLI-luciferase were incubated for 8 h with the indicated agents and processed for luciferase activity measurements. Graph shows mean  $\pm$  SEM percentage of normalized luciferase intensity compared with control (incubated with vehicle only);  $n = 5$ ; \* $P < 0.05$ ; ns: not significant.







**Fig. S5.** Stimulation of voltage-gated Na<sup>+</sup> channels does not affect PKA activity in the neural plate. Neural plates were incubated for 30 min with indicated agents and processed for PKA activity measurements with a nonradioactive PKA assay. Image is a representative example of PKA activity assay. Graph shows mean  $\pm$  SEM PKA activity (P-substrate/non-P-substrate optical density ratio) for the indicated treatments;  $n \geq 5$ , ns: not significant; \*\*\* $P < 0.0005$  compared with control (incubated with vehicle only).



**Fig. 56.** Specificity of Gli2 and Gli3 antibodies. (A) Western blot assays from wild-type (Control) or Gli3-targeted–morpholino-injected (Gli3-MO) embryos at stage 20 (21.75 hpf) probed with antibody for Gli3 and H2B (loading control). Gli3-FL: Gli3 full length; Gli3-R: Gli3 repressor. Shown is a representative example. (B and C) Western blot assays from wild-type or mGli2-GFP–expressing embryos at stage 13 (14.75 hpf) probed with antibody for Gli2 (goat, R&D Systems) and H2B (loading control). Gli2-FL: Gli2 full length; Gli2-R: Gli2 repressor. Endogenous Gli2 is detectable (C) only when anti-Gli2 is incubated for  $\geq 48$  h and with longer exposure times than for detecting the exogenously expressed mGli2-GFP (B). Shown are representative examples. (D) Two-cell-stage embryos were unilaterally injected with Gli2-MO along with a dextran-Alexa fluor 647 conjugate (blue), grown until stage 20 (21.75 hpf), and then were processed for Gli2 [in green, goat anti-Gli2 (R&D Systems); in red, mouse anti-Gli2 (Genetex)] immunostaining and nuclear labeling (DAPI, gray). Shown is a representative example of a transverse immunostained section of the neural tube (outlined). (Scale bar: 30  $\mu\text{m}$ .)







